Compare LI & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LI | DGX |
|---|---|---|
| Founded | 2015 | 1967 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5B | 20.5B |
| IPO Year | 2020 | 1996 |
| Metric | LI | DGX |
|---|---|---|
| Price | $16.37 | $176.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $21.04 | ★ $196.69 |
| AVG Volume (30 Days) | ★ 4.1M | 883.2K |
| Earning Date | 11-26-2025 | 02-10-2026 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | N/A | ★ 14.49 |
| EPS | 0.62 | ★ 8.51 |
| Revenue | ★ $17,952,966,790.00 | $10,850,000,000.00 |
| Revenue This Year | N/A | $12.37 |
| Revenue Next Year | $26.33 | $3.52 |
| P/E Ratio | $27.08 | ★ $20.88 |
| Revenue Growth | N/A | ★ 13.74 |
| 52 Week Low | $16.11 | $148.70 |
| 52 Week High | $33.12 | $197.55 |
| Indicator | LI | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 35.89 | 45.88 |
| Support Level | $16.82 | $171.18 |
| Resistance Level | $17.74 | $181.23 |
| Average True Range (ATR) | 0.43 | 2.55 |
| MACD | 0.07 | 0.44 |
| Stochastic Oscillator | 6.69 | 56.14 |
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 500,000 NEVs in 2024, accounting for about 4% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.